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INTRODUCTION
Clinical background
Hearing impairment is the most common sensory disorder,affecting one in every 500–1000 newborns (http://hearing.
screening.nhs.uk/nationalprog). It is estimated that about half
of these have a genetic cause, whereas the other half are caused
by environmental factors, such as rubella or CMV infection during
pregnancy, factors associated with prematurity or ototoxic medica-
tion. In most genetic cases, the inheritance pattern is autosomal
recessive (80%), but also autosomal dominant (17%), X-linked
(2–3%) and mitochondrial (o1%) inheritance has been described.
In about 30% of cases, additional clinical and/or physical features
lead to a syndrome diagnosis, but in the remaining 70% the only
finding is hearing impairment in otherwise healthy people.
Non-syndromic hearing loss is genetically very heterogeneous, with
over 150 associated loci and 460 identified causative genes (http://
hereditaryhearingloss.org/). Remarkably, defects in one locus (DFNB1)
account for up to 50% of cases in many populations, which makes this
the most common cause of non-syndromic, prelingual hearing
impairment and deafness. The locus was described for the first
time in 19941 and the first mutations in 1997.2,3 The DFNB1
locus (OMIM* 220290) contains two genes associated with hearing
loss, GJB2 (OMIM*121011) and GJB6 (OMIM*604418), encoding
connexin 26 (CX26) and connexin 30 (CX30), respectively. The
reference sequences are given in Table 1. Connexins aggregate to form
connexons, consisting of six connexin proteins in heteromeric or
homomeric complexes located at gap junctions, and which are
involved in the transport of ions and other low-molecular weight
components between cells.
The severity of hearing impairment is graded as mild (20–40 dB),
moderate (41–55 dB), moderately severe (56–70 dB), severe
(71–95 dB), or profound (495 dB) and may involve low
(o500 Hz), middle (500–2000 Hz), or high (42000 Hz) frequencies.
Non-syndromic hearing impairment caused by mutations in the
genes at the DFNB1 locus is associated with congenital, generally non-
progressive, sensorineural hearing impairment that is moderate to
profound by pure tone audiometry, or auditory brain stem response
testing (ABR). It tends to affect all frequencies. The vast majority of
cases therefore fail Newborn Hearing Screening, but a few rare cases
of later-onset hearing impairment4,5 and some progression of the
hearing loss have been described.6–8 By definition, there are no related
systemic findings identified on medical history and physical
examination. Family history is consistent with autosomal recessive
inheritance, but pseudodominant inheritance should not be
overlooked, especially in marriages where both partners have
hearing loss (deaf–deaf unions).9
Genetic background
The most common mutation in GJB2 associated with deafness varies
around the world according to population. In Caucasians, the
c.35delG is the most frequent mutation, comprising 70% of alleles
in some populations, with a carrier rate of 1–3% in the general
population.7,10–14 The c.167delT mutation is the most common
mutation in the Ashkenazi Jewish population,15,16 c.235delC is
found more frequently in the Japanese populations,17 and p.Trp24*
in the Indian, Bangladeshi, Romany, and Slovak populations as well as
others.18–22 The splice mutation c.23þ 1G4A is found in several
populations (including Caucasian, Bangladeshi, Egyptian, Algerian,
Czech, Turkish, Mongolian, and Chinese).18,23–28 Snoeckx et al29 have
compiled data from many centres in an effort to try to establish
correlation between genotype and phenotype. They were able to
distinguish between ‘severe’ alleles, which tended to be truncating,
and ‘mild’ alleles, often non-truncating missense or splice mutations,
but many could not be graded due to their relatively rare occurrence
in the population.
Although many mutations have been described within the GJB2
gene, it became clear that there must be additional alleles. Several
investigators described a common, partial deletion (342 kb,
del(GJB6:D13S1830) in the GJB6 gene, which seemed to account
for many of the missing alleles.30–32 Later, it was confirmed that this is
in fact a 309-kb deletion.33 Rarer deletions have subsequently been
identified, all involving a minimally deleted region between GJB6 and
CRYL134–36 (Figure 1).
It should be noted that a few mutations in the GJB2 gene have been
associated with autosomal dominant inheritance (DFNA3),37–39
which may be non-syndromic40 or with associated skin features41–48
in syndromic forms of deafness such as Vohwinkel syndrome,
Keratitis Ichthyosis Deafness, Bart Pumphrey syndrome, Palmo
Plantar Keratoderma, and Hystrix-ichthyosis. These are particular
mutations involving specific residues of the protein.
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Indications for testing and information needed
Any person with bilateral non-syndromic sensorineural hearing
impairment of prelingual onset with no known aetiology can be
offered testing. Cascade testing (successive testing of relatives to
follow the mutations) can be offered where an index case has been
identified, with one or two mutations in the genes at the DFNB1
locus. In addition, partners of index cases as well as partners of
known carriers can also be offered testing. Prenatal diagnosis can be
offered where both parents are identified as carriers of definitely
pathogenic mutations. In our experience, this request is extremely
rare and is not a common practice in many countries.
It is useful to include the following details with a request for
testing: family history and pedigree, imaging results (for example CT
or MRI scan results), audiograms (or ABR for small children),
ethnicity, and consanguinity.
MATERIALS AND METHODS
This article is the output from a Best Practice meeting on deafness caused by
mutations at the DFNB1 locus, organised by the European Molecular Genetics
Quality Network (EMQN; http://www.emqn.org.uk). The EMQN is an
independent organisation based in the United Kingdom that promotes
improvement in the quality of genetic testing by ensuring that diagnostic
molecular genetic laboratory test results are accurate, reliable, and comparable
wherever they are produced. The mechanism for doing this is the organisation
of external quality assessment (EQA) schemes and the development of Best
Practice guidelines. Annual participation in an EQA scheme is necessary for
quality assurance, continuous validation, evaluation of reporting, and
continuous education of laboratory staff. Testing should only be performed
in laboratories that are accredited according to ISO15189 or the equivalent (see
the Organisation for Economic Cooperation and Development (OECD)
Guidelines (http://www.oecd.org/science/biotechnologypolicies/38839788.pdf).
Clinicians and Scientists involved in molecular diagnosis of deafness were
invited to a workshop supported by EMQN in Nijmegen, Netherlands in
October 2009 to discuss and formulate consensus-based Best Practice Guide-
lines for the molecular diagnosis of deafness caused by mutations at the
DFNB1 locus. The meeting was advertised on the EMQN and EuroGentest
websites (http://www.eurogentest.org); it was organised by the EMQN team
responsible for the DFNB1 EQA scheme and attended by 15 clinical and
scientific experts named in the Acknowledgements. Discussions were based
upon a pilot EQA scheme for DFNB1 testing held in 2008–2009 by EMQN.
After the meeting, draft guidelines were circulated for comment to the
attendees and subjected to further revision.
RESULTS AND DISCUSSION
Molecular diagnostic testing at the DFNB1 locus/approaches and
protocols
Laboratory analysis. Analysis of c.35delG alone, or specific combina-
tions of point mutations, is no longer considered sufficient for
diagnostic testing. In some laboratories, it may be desirable to screen
for specific prevalent mutations first, but in the absence of biallelic
mutations it is recommended that all possible mutations should be
screened, for adequate diagnostic testing. This entails sequence
analysis of the coding sequence (exon 2) and analysis of the splice
sites (50 and 30 ends of intron 1), as well as detection of common
deletions in the GJB6 gene associated with recessive non-syndromic
hearing loss. The multiplex PCR assay designed by del Castillo et al36
is used to detect the del(GJB6-D13S1830) and del(GJB6-D13S1854).
These deletions are relatively common in some populations,30,49–52
but appear to be very rare in others53–57 and should be sought at least
in those in whom only a single mutation has been found on GJB2
screening. GeneClinics advises that very few individuals (o0.5%) will
be homozygous for two GJB6 deletion alleles;58 however, as the assay
is straightforward, consanguinity not uncommon and ethnic origin
not always stated, we suggest that this is done in all cases. The MLPA
kit made by MRC Holland, Amsterdam, Netherlands, (P163-D1
GJB-WFS1) allows the detection of large GJB6 deletions, but as it
lacks the specific probes for del(GJB6-D13S1830) and del(GJB6-
D13S1854) it cannot detect them explicitly; although there are
added probes for specific point mutations such as c.35delG,
c.23þ 1G4A, c.167delT, c.235delC, and c.313_326del, these are
insufficient for comprehensive diagnostic testing in our opinion. In
addition, the P163-D1 kit includes probes for other genes that are not
associated with deafness caused by mutations in the genes at the
DFNB1 locus, including progressive syndromic forms of deafness,
which has the inherent risk of overtesting.
As point mutations in the GJB6 gene have been associated with
syndromic deafness, including skin abnormalities, rather than
non-syndromic forms of deafness, sequencing of this gene is not
recommended in DFNB1 analysis and is also considered to be
overtesting. See Box 1 for an overview.
Reporting. Reports should contain concise background information,
an outline of the techniques and strategy used for screening, and
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Figure 1 Summary of the deletions identified at the DFNB1 locus. Adapted from Wilch et al.34 g. numbering is according to NCBI built 37 (GRCh37)
del(GJB6-D13S1830)¼ chr13: g.20797177_21105945del B309kb30–32 del(GJB6-D13S1854)¼ chr13: g.20802727_21034768delB232kb36 del(DFNB1-
131kb)¼ chr13: g.20939343_21070698del B131kb34 del(DFNB1 4920kb)¼ chr13: g.(20132969–20143922)_(21063547–21065406)del 4920kb35.
Table 1 Accession numbers for the GJB2 and the GJB6 genes
GenBank accession Swiss-Prot
GJB2 (exons 1 and 2) NM_004004.5 CX26: P29033.3
GJB6 (exons 3, 5, and 6) NM_006783.4 CX30: O95452
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prominent display of results together with interpretation of the
findings. Although most laboratories write reports to the referring
clinical geneticists, it is very likely that in future, reports may be sent
directly to general physicians and paediatricians. It is suggested that
ideally reports should be on a single page. Guidelines already exist, for
example, those of the OECD (http://www.oecd.org/science/biotech-
nologypolicies/38839788.pdf), the Swiss Society of Medical Genetics
(http://www.sgmg.ch), and the UK Clinical Molecular Genetics
Society (www.cmgs.org); however, the following relates specifically
to deafness caused by mutations at the DFNB1 locus. See Box 1 for an
overview.
(i) Nomenclature. Mutations should be annotated according to the
Human Genome Variation Society (HGVS) guidelines. Although
numerous publications over the years have reported mutations using
different nomenclatures, it is important to name the ‘known’
mutations following HGVS. Furthermore, it is necessary to indicate
the reference sequence and version number used for annotation.
(http://www.hgvs.org/mutnomen/). Mutation nomenclature can be
checked using programmes such as Mutalyzer and Alamut. For
example, 30delG should be named c.35delG, 310del14 (also known
as 312del14, 314del14) should be named c.313_326del, and
-3172G4A (also known as 3172 or IVS1þ 1G4A) should be
c.23þ 1G4A. It is still acceptable to refer to old nomenclature as
long as HGVS is also indicated. In addition, any new variant should
be annotated according to HGVS guidelines. For reporting purposes,
it is recommended to use annotation at both the nucleotide and the
protein level, as different nucleotide changes can lead to the same
change at the protein level due to the degenerate code at the third
nucleotide of a codon.
Once mutations have been found, testing of parents is recom-
mended to establish phase and recurrence risks (there is the possibility
of de novo mutation, large deletion, uniparental disomy, or allelic
dropout). When genotypes are reported, phase should be considered,
for example, c.[35delG];[139G4T] indicates that the mutations are
known to be on different alleles, whereas c.[35delG(;)139G4T]
indicates that phase is unknown, and c.[35delG];[(35delG)] denotes
a homozygous 35delG, not confirmed by analysis of both parents.
There is considerable difficulty, however, in using HGVS for the
well-known deletions including those found in the GJB6 gene (http://
www.hgvs.org/mutnomen/uncertain.html#exondel). We suggest that
for reporting purposes, it is acceptable to use original deletion names
that is, del(GJB6-D13S1830). The combination of a mutation in GJB2
and a deletion in GJB6 should be described as a compound
heterozygote, instead of a double heterozygote, because the deletions
likely involve a regulatory element of GJB2. Therefore, a common
genotype might be described as [GJB2:c.35delG];[GJB6:del(GJB6-
D13S1830)].
When an MLPA kit has been used to identify deletions, it is not
possible to be sure of the exact breakpoint of the deletions detected,
and therefore, we suggest that for reporting purposes deletions
detected using MLPA should be validated using the multiplex PCR
method described by del Castillo et al.36
(ii) Mutations and variants of unknown clinical significance. Altera-
tions at the DFNB1 locus can be classified as truncating and non-
truncating. New variants, if predicted to lead to premature stop
codon, frameshift, or splicing alteration with abolition of the
obligatory AG/GT sites, all presumed to interfere with proper protein
production, should be labelled as pathogenic or truncating alterations.
More difficult are the novel missense or synonymous changes. In
laboratory reports, an interpretation should be made as to the
predicted functional effect of the variant, following the guidelines of
the Clinical Molecular Genetics Society (http://cmgs.org/). See also
Table 1.
(iii) Controversial known variants. A few variants are notoriously
difficult to interpret, the most well-known example being the
c.101T4C p.(Met34Thr) variant. This variant has been labelled as
autosomal dominant, autosomal recessive, and a neutral variant, but
current evidence suggests it is most likely to be a hypomorphic
recessive allele3,29,59,60 (not fully inactivating the protein). Indeed,
Snoeckx et al29 have shown that 38 patients who were genotyped
c.[35delG];[c.101T4C] had mild to moderate hearing loss. If the
mutation had no specific influence on the phenotype, this would have
resulted in a variety of degrees of hearing loss. Moreover, the high
prevalence of this variant in the general Caucasian population (carrier
rate of 1/37–1/43)11,14,52 and its under-representation in several
cohorts with profound deafness, supports its role as a hypomorphic
allele rather than a mutation responsible for severe to profound
hearing loss. Therefore, if p.(Met34Thr) is present in homozygosity,
or with another pathogenic mutation in a patient with mild hearing
loss, it is likely to be causative; if the hearing loss is profound however,
another cause should be considered.
For p.(Val37Ile), evidence now suggests that it is a common
mutation causing mild–moderate hearing loss, especially, in subjects
from Southeast Asia and North Africa61; the variant should be
reported as such. The variants p.(Arg127His), p.(Val27Ile),
p.(Lys224Gln), and p.(Val153Ile) appear to be non-pathogenic
polymorphic variants.
(iv) Interpretation. This is the final step in reporting and is the
professional role of the diagnostic laboratory. For diagnostic testing,
the common situations include:
(1) Two mutations found (both pathogenic, or one pathogenic and
one unknown); the results confirm (if mutations are shown to be
in trans) or support the diagnosis (if phase is unknown). It is good
practice to mention the effect of some of the milder mutations
(see above, and Table 2). The report should recommend clinical
genetic counselling when one or two mutations are detected.
Carrier screening can be offered to other family members.
Box 1 Standards for diagnostic testing and reporting of mutations
at the DFNB1 locus
Screening Direct sequencing of coding exon 2
Analysis of splice sites
Exclusion of common deletions encompassing GJB6, confirmed by
multiplex PCR if MLPA is first screened
Reporting Report should ideally be no more than one page
Brief description of methods used
Expected sensitivity of the methods, particularly, where one or no
mutations are found.
Reference sequence and version used to denote numbering of
nucleotides
Mutation given at nucleotide level with predicted protein effect
Use of HGVS nomenclature for description of variants/mutations
(See suggestions for common deletions)
Brief interpretation of findings and further recommendations
Abbreviation: HGVS, the Human Genome Variation Society.
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(2) No mutation is found; hearing impairment is genetically very
heterogeneous, therefore, this result does not exclude other
genetic or acquired causes of hearing impairment in this patient.
The sensitivity of the test strategy should be given; sequencing
GJB2 (noncoding and coding exons) and screening for del(GJB6-
D13S1830) gives498% mutation detection rate. For parents of a
deaf child who does not have mutations at DFNB1, residual
recurrence risk should be estimated. This is likely to be a
minimum of 10% but up to 25% (as for any recessive disorder).
(3) One mutation found; the patient is a carrier, which supports the
diagnosis, but for mutations with high frequencies this can be a
coincidental finding. In familial cases (siblings) where one
mutation is found, haplotype analysis (marker analysis) may be
recommended. If haplotype analysis shows all affected siblings to
have inherited the same alleles from their parents, the diagnosis of
hearing loss caused by a gene at the DFNB1 locus is supported,
but if not, carrier status is likely to be coincidental to the
aetiology of hearing loss. Suggested markers for this analysis are
D13S141-(GJB2-GJB6)-D13S175-D13S143-D13S1236, although
other markers could be useful as well.
(4) New missense variation: audiometry of the parents may be
recommended when they carry the variant in order to exclude
dominant inheritance. In contrast, if a single new missense
variant is shown to have arisen de novo, then it is possible that
it may be a pathogenic autosomal dominant mutation.
Carrier testing is usually performed in the case of cascade testing
(successive testing of family members to follow the mutation), and
genetic counselling is part of the recommendation if the subject is
found to have a mutation. Partners of carriers should be offered
testing as well, because of the high incidence of carriers in the general
population.
CONCLUSIONS
Diagnostic testing for DFNB1-associated hearing impairment is
technically simple compared with many diagnostic tests and has a
good diagnostic yield (up to 15–20% of singleton cases and 50% of
recessively inherited cases of deafness). We have made recommenda-
tions for good practice for diagnostic testing of this locus, as well as
reporting of the results, which includes sequence analysis of the
coding region of the GJB2 gene, as well as of the splice sites and a
search for common deletions involving GJB6. Nomenclature of
mutations should follow HGVS guidelines, and mutations should
be annotated at the protein and cDNA level. It is the role of the
diagnostic laboratory to provide an interpretation of the results when
reporting.
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